Longboard Pharmaceuticals, Inc. Stock price
Equities
LBPH
US54300N1037
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.6 USD | +2.96% | +8.16% | +258.21% |
Financials (USD)
Sales 2024 * | 2.5M | Sales 2025 * | - | Capitalization | 778M |
---|---|---|---|---|---|
Net income 2024 * | -73M | Net income 2025 * | -104M | EV / Sales 2024 * | 227 x |
Net cash position 2024 * | 210M | Net cash position 2025 * | 263M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-8.15
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.24% |
Latest transcript on Longboard Pharmaceuticals, Inc.
1 day | +2.96% | ||
1 week | +8.16% | ||
Current month | -2.61% | ||
1 month | -9.77% | ||
3 months | +248.39% | ||
6 months | +293.44% | ||
Current year | +258.21% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 20-01-02 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 20-12-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 20-11-30 |
Director/Board Member | 68 | 20-11-30 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.41% | 4 M€ | -5.15% | - | |
0.00% | 36 M€ | +4.92% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 21.6 | +2.96% | 326,906 |
24-03-27 | 20.98 | +4.33% | 354,106 |
24-03-26 | 20.11 | +1.36% | 280,970 |
24-03-25 | 19.84 | -0.70% | 408,319 |
24-03-22 | 19.98 | +0.05% | 398,302 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+258.21% | 778M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |